Prognostic  ||| S:0 E:11 ||| JJ
value  ||| S:11 E:17 ||| NN
of  ||| S:17 E:20 ||| IN
inhibitor  ||| S:20 E:30 ||| NN
of  ||| S:30 E:33 ||| IN
apoptosis  ||| S:33 E:43 ||| JJ
protein  ||| S:43 E:51 ||| NN
family  ||| S:51 E:58 ||| NN
expression  ||| S:58 E:69 ||| NN
in  ||| S:69 E:72 ||| IN
patients  ||| S:72 E:81 ||| NNS
with  ||| S:81 E:86 ||| IN
acute  ||| S:86 E:92 ||| JJ
myeloid  ||| S:92 E:100 ||| NNS
leukemia  ||| S:100 E:109 ||| VBP
The  ||| S:109 E:113 ||| DT
inhibitor  ||| S:113 E:123 ||| NN
of  ||| S:123 E:126 ||| IN
apoptosis  ||| S:126 E:136 ||| JJ
protein  ||| S:136 E:144 ||| NN
( ||| S:144 E:145 ||| -LRB-
IAP ||| S:145 E:148 ||| NNP
)  ||| S:148 E:150 ||| -RRB-
family  ||| S:150 E:157 ||| NN
acts  ||| S:157 E:162 ||| NNS
as  ||| S:162 E:165 ||| IN
an  ||| S:165 E:168 ||| DT
inhibitor  ||| S:168 E:178 ||| NN
of  ||| S:178 E:181 ||| IN
apoptosis  ||| S:181 E:191 ||| JJ
pathways ||| S:191 E:199 ||| NN
.  ||| S:199 E:201 ||| .
The  ||| S:201 E:205 ||| DT
potential  ||| S:205 E:215 ||| JJ
prognostic  ||| S:215 E:226 ||| JJ
value  ||| S:226 E:232 ||| NN
of  ||| S:232 E:235 ||| IN
the  ||| S:235 E:239 ||| DT
expression  ||| S:239 E:250 ||| NN
of  ||| S:250 E:253 ||| IN
selected  ||| S:253 E:262 ||| JJ
IAP  ||| S:262 E:266 ||| NNP
family  ||| S:266 E:273 ||| NN
members ||| S:273 E:280 ||| NNS
,  ||| S:280 E:282 ||| ,
XIAP ||| S:282 E:286 ||| NNP
,  ||| S:286 E:288 ||| ,
cIAP-1 ||| S:288 E:294 ||| NNP
,  ||| S:294 E:296 ||| ,
cIAP-2  ||| S:296 E:303 ||| NNP
and  ||| S:303 E:307 ||| CC
survivin  ||| S:307 E:316 ||| JJ
protein ||| S:316 E:323 ||| NN
,  ||| S:323 E:325 ||| ,
was  ||| S:325 E:329 ||| VBD
evaluated  ||| S:329 E:339 ||| VBN
with  ||| S:339 E:344 ||| IN
regard  ||| S:344 E:351 ||| NN
to  ||| S:351 E:354 ||| TO
treatment  ||| S:354 E:364 ||| NN
response  ||| S:364 E:373 ||| NN
and  ||| S:373 E:377 ||| CC
survival  ||| S:377 E:386 ||| NN
of  ||| S:386 E:389 ||| IN
56  ||| S:389 E:392 ||| CD
newly  ||| S:392 E:398 ||| RB
diagnosed  ||| S:398 E:408 ||| JJ
adult  ||| S:408 E:414 ||| NN
patients  ||| S:414 E:423 ||| NNS
with  ||| S:423 E:428 ||| IN
acute  ||| S:428 E:434 ||| JJ
myeloid  ||| S:434 E:442 ||| JJ
leukemia  ||| S:442 E:451 ||| NN
( ||| S:451 E:452 ||| -LRB-
AML ||| S:452 E:455 ||| NNP
) ||| S:455 E:456 ||| -RRB-
.  ||| S:456 E:458 ||| .
The  ||| S:458 E:462 ||| DT
presence  ||| S:462 E:471 ||| NN
of  ||| S:471 E:474 ||| IN
these  ||| S:474 E:480 ||| DT
IAP  ||| S:480 E:484 ||| NNP
members  ||| S:484 E:492 ||| NNS
influenced  ||| S:492 E:503 ||| VBD
the  ||| S:503 E:507 ||| DT
achievement  ||| S:507 E:519 ||| NN
of  ||| S:519 E:522 ||| IN
a  ||| S:522 E:524 ||| DT
complete  ||| S:524 E:533 ||| JJ
response  ||| S:533 E:542 ||| NN
( ||| S:542 E:543 ||| -LRB-
CR ||| S:543 E:545 ||| NNP
) ||| S:545 E:546 ||| -RRB-
.  ||| S:546 E:548 ||| .
In  ||| S:548 E:551 ||| IN
addition ||| S:551 E:559 ||| NN
,  ||| S:559 E:561 ||| ,
overall  ||| S:561 E:569 ||| JJ
survival  ||| S:569 E:578 ||| NN
( ||| S:578 E:579 ||| -LRB-
OS ||| S:579 E:581 ||| NNP
)  ||| S:581 E:583 ||| -RRB-
was  ||| S:583 E:587 ||| VBD
influenced  ||| S:587 E:598 ||| VBN
by  ||| S:598 E:601 ||| IN
low  ||| S:601 E:605 ||| JJ
survivin  ||| S:605 E:614 ||| JJ
expression  ||| S:614 E:625 ||| NN
in  ||| S:625 E:628 ||| IN
univariate  ||| S:628 E:639 ||| NN
and  ||| S:639 E:643 ||| CC
multivariate  ||| S:643 E:656 ||| JJ
analysis  ||| S:656 E:665 ||| NN
( ||| S:665 E:666 ||| -LRB-
p  ||| S:666 E:668 ||| CD
=  ||| S:668 E:670 ||| SYM
0.014  ||| S:670 E:676 ||| CD
and  ||| S:676 E:680 ||| CC
p  ||| S:680 E:682 ||| NN
=  ||| S:682 E:684 ||| SYM
0.013 ||| S:684 E:689 ||| CD
,  ||| S:689 E:691 ||| ,
respectively ||| S:691 E:703 ||| RB
) ||| S:703 E:704 ||| -RRB-
.  ||| S:704 E:706 ||| .
A  ||| S:706 E:708 ||| DT
strong  ||| S:708 E:715 ||| JJ
correlation  ||| S:715 E:727 ||| NN
was  ||| S:727 E:731 ||| VBD
observed  ||| S:731 E:740 ||| VBN
between  ||| S:740 E:748 ||| IN
members  ||| S:748 E:756 ||| NNS
of  ||| S:756 E:759 ||| IN
the  ||| S:759 E:763 ||| DT
IAP  ||| S:763 E:767 ||| NNP
family  ||| S:767 E:774 ||| NN
( ||| S:774 E:775 ||| -LRB-
XIAP  ||| S:775 E:780 ||| NNP
and  ||| S:780 E:784 ||| CC
cIAP-1 ||| S:784 E:790 ||| NNP
,  ||| S:790 E:792 ||| ,
XIAP  ||| S:792 E:797 ||| NNP
and  ||| S:797 E:801 ||| CC
cIAP-2 ||| S:801 E:807 ||| NNP
,  ||| S:807 E:809 ||| ,
cIAP-1  ||| S:809 E:816 ||| NNP
and  ||| S:816 E:820 ||| CC
cIAP-2 ||| S:820 E:826 ||| NNP
,  ||| S:826 E:828 ||| ,
p  ||| S:828 E:830 ||| JJ
< ||| S:830 E:832 ||| SYM
0.001  ||| S:832 E:838 ||| NN
for  ||| S:838 E:842 ||| IN
all  ||| S:842 E:846 ||| DT
comparisons ||| S:846 E:857 ||| NNS
) ||| S:857 E:858 ||| -RRB-
,  ||| S:858 E:860 ||| ,
while  ||| S:860 E:866 ||| IN
Smac ||| S:866 E:870 ||| NNP
/ ||| S:870 E:871 ||| NNP
DIABLO  ||| S:871 E:878 ||| NNP
demonstrated  ||| S:878 E:891 ||| VBD
an  ||| S:891 E:894 ||| DT
inverse  ||| S:894 E:902 ||| JJ
correlation  ||| S:902 E:914 ||| NN
with  ||| S:914 E:919 ||| IN
XIAP ||| S:919 E:923 ||| NNP
,  ||| S:923 E:925 ||| ,
cIAP-1  ||| S:925 E:932 ||| NNP
and  ||| S:932 E:936 ||| CC
cIAP-2  ||| S:936 E:943 ||| NNP
( ||| S:943 E:944 ||| -LRB-
p  ||| S:944 E:946 ||| JJ
< ||| S:946 E:948 ||| SYM
0.001  ||| S:948 E:954 ||| NN
for  ||| S:954 E:958 ||| IN
all  ||| S:958 E:962 ||| DT
comparisons ||| S:962 E:973 ||| NNS
) ||| S:973 E:974 ||| -RRB-
.  ||| S:974 E:976 ||| .
Further  ||| S:976 E:984 ||| JJ
studies  ||| S:984 E:992 ||| NNS
should  ||| S:992 E:999 ||| MD
be  ||| S:999 E:1002 ||| VB
undertaken  ||| S:1002 E:1013 ||| VBN
to  ||| S:1013 E:1016 ||| TO
better  ||| S:1016 E:1023 ||| RB
demonstrate  ||| S:1023 E:1035 ||| VB
the  ||| S:1035 E:1039 ||| DT
mode  ||| S:1039 E:1044 ||| NN
of  ||| S:1044 E:1047 ||| IN
action  ||| S:1047 E:1054 ||| NN
of  ||| S:1054 E:1057 ||| IN
IAP  ||| S:1057 E:1061 ||| NNP
members ||| S:1061 E:1068 ||| NNS
,  ||| S:1068 E:1070 ||| ,
as  ||| S:1070 E:1073 ||| RB
well  ||| S:1073 E:1078 ||| RB
as  ||| S:1078 E:1081 ||| IN
their  ||| S:1081 E:1087 ||| PRP$
prognostic  ||| S:1087 E:1098 ||| NN
and  ||| S:1098 E:1102 ||| CC
therapeutic  ||| S:1102 E:1114 ||| JJ
potentials ||| S:1114 E:1124 ||| NN
.  ||| S:1124 E:1126 ||| .
